Genentech: The US patent on trastuzumab ("Herceptin") expires in June of 2019, so only Genentech is allowed to produce it. In Europe, the patent expired in June of 2014, but I don't know if the European Medicines Agency has yet approved any biosimilars ("generics").
Answered 9/17/2015
2.3k views
5 doctors weighed in across 2 answers
A doctor has provided 1 answer
3 doctors weighed in across 2 answers
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question